CR10617A - Derivados de oxazolidona como moduladores pr - Google Patents

Derivados de oxazolidona como moduladores pr

Info

Publication number
CR10617A
CR10617A CR10617A CR10617A CR10617A CR 10617 A CR10617 A CR 10617A CR 10617 A CR10617 A CR 10617A CR 10617 A CR10617 A CR 10617A CR 10617 A CR10617 A CR 10617A
Authority
CR
Costa Rica
Prior art keywords
hormone
compounds
modulators
uterine
oxazolidone derivatives
Prior art date
Application number
CR10617A
Other languages
English (en)
Inventor
Thomas Joseph Commons
Andrew Fensome
Gavin David Heffernan
Casey Cameron Mccomas
Richard Page Woodworth Jr
Michael Byron Webb
Michael Anthony Marella
Edward George Melenski
Ronald Charles Bernotas
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR10617A publication Critical patent/CR10617A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos de la estructura (I), en donde R1, R2, R5, R6, V, X, Y, Z y Q se describen aqui, o su sal farmaceuticamente aceptable, tautomero, metabolito o profarmaco. Estos compuestos son utiles para tratar una variedad de afecciones relacionadas con hormonas que incluyen contracepcion tratar o prevenir miomas uterinos, endometriosis, metrorragia disfuncional, liomiomata uterino, sindrome de ovario poliquistico, o carcinomas dependientes de hormona, que proporciona hormonoterapia restitutiva, que estimula la ingestion de alimento o sincronizacion del estro.
CR10617A 2006-08-15 2009-02-13 Derivados de oxazolidona como moduladores pr CR10617A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83789806P 2006-08-15 2006-08-15

Publications (1)

Publication Number Publication Date
CR10617A true CR10617A (es) 2009-03-12

Family

ID=39082681

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10617A CR10617A (es) 2006-08-15 2009-02-13 Derivados de oxazolidona como moduladores pr

Country Status (22)

Country Link
US (1) US7618990B2 (es)
EP (1) EP2054410A2 (es)
JP (1) JP2010500409A (es)
KR (1) KR20090039774A (es)
CN (1) CN101501031B (es)
AR (1) AR062327A1 (es)
AU (1) AU2007284599B2 (es)
BR (1) BRPI0716622A2 (es)
CA (1) CA2659208A1 (es)
CR (1) CR10617A (es)
GT (1) GT200900032A (es)
IL (1) IL196886A0 (es)
MX (1) MX2009001698A (es)
NO (1) NO20090457L (es)
NZ (1) NZ574753A (es)
PE (1) PE20070753A1 (es)
RU (1) RU2009105113A (es)
SA (1) SA07280440B1 (es)
SV (1) SV2009003168A (es)
TW (1) TW200815428A (es)
WO (1) WO2008021331A2 (es)
ZA (1) ZA200901055B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081803A1 (es) * 2007-03-09 2008-12-11 Wyeth Corp Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
PE20090167A1 (es) * 2007-03-09 2009-02-11 Wyeth Corp Sintesis y caracterizacion de la forma iii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
CN101525310B (zh) * 2009-04-21 2019-04-16 大连九信精细化工有限公司 1-苯甲酰基-3-(2-羟基-1，1-二甲基乙基)硫脲的合成方法
US9133182B2 (en) * 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
WO2012082672A2 (en) * 2010-12-14 2012-06-21 Merck Sharp & Dohme Corp. Process and intermediates for preparing macrolactams
SMT202300205T1 (it) * 2014-07-03 2023-09-06 Celgene Quanticel Research Inc Inibitori della demetilasi lisina-specifica-1
BR112022019178A2 (pt) * 2020-03-26 2022-11-01 Janssen Pharmaceutica Nv Aminociclobutanos como moduladores da monoacilglicerol lipase
CN118146123A (zh) * 2024-02-04 2024-06-07 河北鼎泰制药有限公司 一种盐酸安罗替尼中间体的合成方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670338A1 (de) 1966-03-14 1972-08-10 Heyden Chem Fab Verfahren zur Herstellung von antimikrobiell wirksamen Nitrofuranderivaten
US3493565A (en) 1966-03-14 1970-02-03 Squibb & Sons Inc 3-amino-5-(nitrofuryl)-1,2,4-oxadiazole derivatives
NL6809997A (es) * 1967-08-04 1969-02-06
GB1224995A (en) 1968-09-20 1971-03-10 Delalande Sa New 5-propargyloxymethyl-2-substituted oxazolidinones and their process of preparation
US4293558A (en) * 1975-10-28 1981-10-06 Eli Lilly And Company Antiviral thiazolinyl benzimidazoles and derivatives
CA1076582A (en) * 1975-10-28 1980-04-29 Charles J. Paget Antiviral thiazolinyl or thiazinyl ketobenzimidazoles
US4008243A (en) * 1975-11-19 1977-02-15 Eli Lilly And Company Antiviral thiazolinyl or thiazinyl benzimidazole esters
US4268679A (en) * 1980-02-19 1981-05-19 Ppg Industries, Inc. 3-[5- or 3-Substituted-5- or 3-isoxazolyl]-1-allyl or alkyl-4-substituted-5-substituted or unsubstituted-2-imidazolidinones
US4426527A (en) * 1982-02-12 1984-01-17 Ppg Industries, Inc. 3-[5- Or 3-substituted-1,2,4-oxadiazol-3- or -5-yl]-1-substituted-4-substituted-5-substituted or unsubstituted-2-imidazolidinones
DE3227329A1 (de) 1982-07-22 1984-01-26 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von 2-n,n-disubstituierten aminothiazolen
US4756744A (en) * 1985-06-24 1988-07-12 Ppg Industries, Inc. Herbicidally active 4-aminoalkylamino-3-isoxazolyl-2-imidazolidinone derivatives
DE3723797A1 (de) 1987-07-18 1989-01-26 Merck Patent Gmbh Oxazolidinone
EP0557408A4 (en) 1990-11-06 1993-10-27 Smith-Kline Beecham Corporation Imidazolidinone compounds
DE69132006T2 (de) 1990-11-30 2000-08-03 Otsuka Pharmaceutical Co., Ltd. Thiazolederivate als inhibitoren von aktivem sauerstoff
DE4335876A1 (de) * 1993-10-17 1995-04-20 Schering Ag Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen
JPH07149745A (ja) 1993-11-30 1995-06-13 Hisamitsu Pharmaceut Co Inc 新規な２−アミノチアゾール誘導体
WO1995015955A1 (de) 1993-12-06 1995-06-15 Basf Aktiengesellschaft 2,4-diaminothiazole und ihre herstellung
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
DE19540027A1 (de) 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
US5714607A (en) * 1995-12-01 1998-02-03 American Cyanamid Company Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide
DE19601264A1 (de) * 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19649095A1 (de) 1996-02-06 1997-08-07 Bayer Ag Neue Heteroaryl-Oxazolidinone
HRP970049A2 (en) 1996-02-06 1998-04-30 Bayer Ag New heteroaryl oxazolidinones
DE19604223A1 (de) 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
US5972372A (en) * 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
CA2262502C (en) 1996-07-31 2002-11-26 Nikken Chemicals Co., Ltd. 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same
US5819742A (en) * 1996-11-06 1998-10-13 Family Health International Vaginal device for preventing conception or the transmission of sexually transmitted diseases, or both
DE19732928C2 (de) 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
ATE257703T1 (de) * 1997-10-27 2004-01-15 Takeda Chemical Industries Ltd 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
US6562844B2 (en) * 1998-01-23 2003-05-13 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
US6239152B1 (en) * 1998-01-23 2001-05-29 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
AU3289299A (en) 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents
JP2001261652A (ja) 2000-03-21 2001-09-26 Suntory Ltd 二置換イミノヘテロサイクリック化合物
EP1268474A2 (en) 2000-03-30 2003-01-02 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
GB0009803D0 (en) * 2000-04-25 2000-06-07 Astrazeneca Ab Chemical compounds
DE10034622A1 (de) 2000-07-17 2002-01-31 Bayer Ag Substituierte Imidazol-Derivate und deren Verwendung zur Herstellung von Arzneimitteln
DE10034623A1 (de) 2000-07-17 2002-01-31 Bayer Ag Heterocyclisch substituierte Pyridine als Cytokin-Inhibitoren
DE10034628A1 (de) 2000-07-17 2002-01-31 Bayer Ag Pyridinhaltige Oxazolidinone als Cytokin-Inhibitoren
US20020115669A1 (en) * 2000-08-31 2002-08-22 Wiedeman Paul E. Oxazolidinone chemotherapeutic agents
FR2823209B1 (fr) 2001-04-04 2003-12-12 Fournier Lab Sa Nouvelles thiohydantoines et leur utilisation en therapeutique
GB0118407D0 (en) 2001-07-27 2001-09-19 Cipla Ltd Oxazolidinone derivatives as antibacterial agents
KR100437972B1 (ko) * 2001-10-27 2004-07-02 한국과학기술연구원 피롤리디논 유도체, 이의 제조 방법 및 이를 포함하는제약 조성물
US7119111B2 (en) 2002-05-29 2006-10-10 Amgen, Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use
BR0313160A (pt) 2002-08-08 2005-07-12 Smithkline Beecham Corp Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
US7109227B2 (en) * 2002-08-26 2006-09-19 National Health Research Institutes Imidazolamino compounds
WO2004019938A1 (en) 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
US20040167192A1 (en) * 2003-01-16 2004-08-26 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
US7169797B2 (en) * 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
EP1610793A2 (en) 2003-03-25 2006-01-04 Vertex Pharmaceuticals Incorporated Thiazoles useful as inhibitors of protein kinases
AU2004228057A1 (en) 2003-04-03 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
KR20060057569A (ko) 2003-07-08 2006-05-26 아스트라제네카 아베 알파7 니코틴계 아세틸콜린 수용체와 친화도를 갖는스피로[1-아자비시클로[2.2.2]옥탄-3,5'-옥사졸리딘-2'-온] 유도체

Also Published As

Publication number Publication date
ZA200901055B (en) 2009-12-30
CN101501031A (zh) 2009-08-05
NO20090457L (no) 2009-04-27
CA2659208A1 (en) 2008-02-21
RU2009105113A (ru) 2010-09-27
GT200900032A (es) 2011-03-29
US7618990B2 (en) 2009-11-17
CN101501031B (zh) 2012-02-01
WO2008021331A3 (en) 2008-05-22
BRPI0716622A2 (pt) 2013-10-08
SV2009003168A (es) 2010-01-14
TW200815428A (en) 2008-04-01
EP2054410A2 (en) 2009-05-06
AU2007284599B2 (en) 2011-07-21
IL196886A0 (en) 2009-11-18
PE20070753A1 (es) 2008-08-14
AR062327A1 (es) 2008-10-29
JP2010500409A (ja) 2010-01-07
AU2007284599A1 (en) 2008-02-21
KR20090039774A (ko) 2009-04-22
SA07280440B1 (ar) 2010-10-20
MX2009001698A (es) 2009-02-25
NZ574753A (en) 2011-04-29
WO2008021331A2 (en) 2008-02-21
US20080045556A1 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
CR10617A (es) Derivados de oxazolidona como moduladores pr
ECSP055574A (es) Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas.
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
CO6410259A2 (es) Preparaciones para la sincronización de ciclo estral y protocolos sin cidr efectivos
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
CY1110989T1 (el) Χρηση 3-(4-αμινο-1-οξο-1,3-διυδρο-ισοϊνδολ-2-υλο)-πιπεριδινο-2,6-διονης για την αντιμετωπιση λεμφωματων κυτταρων του μανδυα
CR20190531A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UA122873C2 (uk) Контрацептивний засіб на основі дроспіренону для пацієнтки, що страждає від надлишкової маси тіла
WO2008021339A3 (en) Pyrrolidine and related derivatives useful as pr modulators
TN2017000482A1 (en) Selective progesterone receptor modulator (sprm) regimen.
CR9627A (es) Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof
CY1121190T1 (el) Δοσολογικη μορφη ανταγωνιστη υποδοχεα προγεστερονης
NO20080441L (no) Benzofuranonderivater som ikke-steroide progesteronreseptormodulatorer
PA8848001A1 (es) Pirrolidinas
JP2015535282A5 (es)
EA201000097A1 (ru) 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов
MX2009009515A (es) Cianopirrol sulfonamidas utiles para la modulacion del receptor de progesterona.
TN2013000526A1 (en) Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation
EA200702524A1 (ru) Нестероидные модуляторы рецептора прогестерона
CL2008003070A1 (es) Metodo de tratamiento de hemorragia uterina disfuncional que comprende administrar a un paciente una cantidad eficaz de una composicion que comprende un compuesto derivado de antagonistas de progesterona.
EA201990859A1 (ru) Ингибиторы глюкокортикоидного рецептора
TH85615A (th) สารปรับโพรเจสเตอโรนรีเซปเตอร์ชนิดนอนสเตียรอยด์
CL2012001723A1 (es) Compuestos derivados de aminoalquilpirimidina, antagonistas del receptor h4 de histamina; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento o la prevencion de una enfermedad alergica; inmunologica o inflamatoria, del dolor o del cancer.